9; 1 and has now fallen 3 days in a row. Announces Pricing of $86.0 Million Registered Direct Offering Priced ... Jaguar Health Signs Memorandum of Understanding with the Lead Sponsor of the Planned ... TransEnterix Announces New Training Center in EU... Castor Maritime Inc. SEATTLE, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced that it has received $21 million from the exercise of outstanding warrants. If you continue to use this site we will assume that you are happy with it. December 17, 2020 - 9:15 am. Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. Unsubscribe any time. We respect your email privacy. 1)* Atossa Therapeutics, Inc. (Name of Issuer) Common Stock, $0.18 par value per share (Title of Class of Securities) 04962H506 (CUSIP Num 2 ATOS / Atossa Genetics Inc / CVI Investments, Inc. - SC 13G Passive Investment Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Accomplishments and Strategy for 2021, Atossa Therapeutics Announces Two-Year Update of FDA-Approved Expanded Access Treatment with Endoxifen, Atossa Therapeutics’ Phase 2 Endoxifen Breast Cancer Study Produces Substantially Positive Results Allowing Study to be Halted Early. Thank you for your time Following surgery, an additional compassionate use authorization was granted by the FDA for the same patient, who has now continued to take oral Endoxifen in the adjuvant setting following her surgery. We use cookies on our website to enhance the user experience. Atossa has two programs to develop therapies to treat COVID-19: One called the COVID-19 HOPE Program which uses AT-H201 for severely ill patients to improve lung function and reduce the amount of time that COVID-19 patients are on ventilators and another called AT-301 Nasal Spray for at-home use immediately following diagnosis of COVID-19 to proactively reduce symptoms of COVID-19 and to slow the infection rate so that a person’s immune system can more effectively fight the virus. Atossa Therapeutics Contracts for Clinical Study of AT-301 Nasal Spray, Atossa's Second COVID-19 Therapeutic Development Program via: GlobeNewswire News Room (Amendment No. High volatility in Atossa Genetics Inc. stock price on Monday which ended trading at $3.86 (Updated on February 08, 2021) Buy or Hold candidate since 2021-01-13 Gain 227.12% PDF. Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. Copyright © 2021 Atossa Therapeutics, Inc. All Rights Reserved. Get the latest news and breaking stories for Atossa Therapeutics (ATOS) stock. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. Get stock quotes, news, fundamentals and easy to read SEC and SEDI insider filings. Includes articles, videos and real-time news from StockTwits. Forward-Looking Statements Disclaimer Statement. We need to get the stock known so we can get the push we need comment it in places or show them the potential at it , if we look at the graph right now it is primed for a cup and handle move , in FEB 2 we have news coming so if we can get this in a uptrend today the stock is gonna go parabolic it's oversold and undervalued right now so buy more and hold, TO THE MOON BOYS "We are very encouraged by this patient's experience with our Endoxifen over the past two years. Get stock quotes, news, fundamentals and easy to read SEC and SEDI insider filings. The only place for free North American stock rankings incorporating insider commitment. The Atossa Genetics Inc. stock price fell by -0.77% on the last day (Monday, 8th Feb 2021) from $3.89 to $3.86. At the end of 2018, the FDA authorized a single-patient study under its Expanded Access, or compassionate use program, for this breast cancer patient to receive Atossa's oral Endoxifen in the "window of opportunity" between diagnosis of breast cancer and surgery. Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering, the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa's products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time. The only place for free North American stock rankings incorporating insider commitment. The only place for free North American stock rankings incorporating insider commitment. Atossa Therapeutics Inc. historial options data by MarketWatch. SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announces updated findings following 26 months of Expanded Access (or "compassionate use") single-patient studies of Atossa's … "This patient, like many breast cancer patients, was reluctant to take tamoxifen because of the well-documented side effects associated with that drug and because she lacked the proper liver enzymes to properly metabolize tamoxifen," commented Steve Quay, Ph.D., M.D., Atossa's President and CEO. NASDAQ Updated Feb 11, 2021 6:25 PM Pre-Market 0.01 (0.37%) Related to the latest indications, Atossa Therapeutics with ticker code (ATOS) have now 2 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The only place for free North American stock rankings incorporating insider commitment. Real-time trade and investing ideas on Digital Ally Inc. DGLY from the largest community of traders and investors. The only place for free North American stock rankings incorporating insider commitment. Home of the insider insights newsletter and the Canadian Insider Club which offers alerts and premium research. Description: Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in the US. Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of … SEATTLE, Dec. 17, 2020 -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the "Company" or "Atossa"), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced today that it has entered into a securities purchase … View daily, weekly or monthly … Atossa Therapeutics Breast Cancer Drug Shows Overwhelmingly Positive Results, FDA Halts Study Early in Order to Start Clinical Development Yesterday ATOS drug was cleared from the Phase 2 FDA study because the results were so freaking overwhelmingly good. Atossa Therapeutics, Inc. Common Stock (ATOS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. January 6, 2021 - 9:15 am. We are advancing programs to help develop treatments that are effective and affordable. Her experience serves as a model for ongoing development efforts.". We are developing the promise of endoxifen and exploiting its potential to both help prevent as well as to treat breast cancer with our proprietary Topical and Oral Endoxifen. SEATTLE, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the "Company" or "Atossa"), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced today that it has entered into a … Copyright © 2021 StockTitan.net - All rights reserved. Home of the insider insights newsletter and the Canadian Insider Club which offers alerts and premium research. Atossa Therapeutics Inc. ATOS 3.31 0.17 (4.89%). The range between the high target price and low target price is between 7.5 and 5 calculating the average target price we see 6.25. Discover historical prices for ATOS stock on Yahoo Finance. Tenax Therapeutics Inc. TENX 2.69 0.09 (3.24%). It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19. "To date, the patient has not had a recurrence of breast cancer, as assessed by clinical breast examination and mammography; has not had treatment-related changes in periodic laboratory blood tests and general clinical examinations; and, the treatment has been well tolerated, including an absence of typical vasomotor symptoms commonly associated with tamoxifen (for example, night sweats and hot flashes), an FDA-approved drug frequently prescribed for breast cancer treatment," commented Sidney Goldblatt, M.D., Principal Investigator. Company Contact:Atossa Therapeutics, Inc.Kyle Guse, CFO and General CounselOffice: 866 893-4927kyle.guse@atossainc.com, Investor Relations Contact:Core IROffice:(516) 222-2560ir@atossainc.com. Atossa Therapeutics - Consensus Indicates Potential 313.9% Upside. Since the … SOS Ltd. Home of the insider insights newsletter and the Canadian Insider Club which offers alerts and premium research. Get stock quotes, news, fundamentals and easy to read SEC and SEDI insider filings. Home of the insider insights newsletter and the Canadian Insider Club which offers alerts and premium research. Atossa Therapeutics Announces Two-Year Update of FDA-Approved Expanded Access Treatment with Endoxifen, Surgical and Medical Instrument Manufacturing, Health Technology,Medical Specialties,Manufacturing,Surgical and Medical Instrument Manufacturing. Get real time news for Nasdaq companies quoted on the stock market, press releases, financial disclosures and multimedia content, for investment community, individual investors and the general public. To learn more about how we use cookie, please read our cookie policy. SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announces updated findings following 26 months of Expanded Access (or "compassionate use") single-patient studies of Atossa's Endoxifen. She has now taken Atossa's oral Endoxifen for approximately 26 months and is continuing to take oral Endoxifen daily under these authorizations. For more information, please visit www.atossatherapeutics.com. View ATOS option chain data and pricing information for given maturity periods. Get stock quotes, news, fundamentals and easy to read SEC and SEDI insider filings. During the day the stock fluctuated 10.14% from a day low at $3.65 to a day high of … Shares of Atossa Therapeutics (ATOS) have done what shares of most companies in the hunt for coronavirus solutions have done in 2020 – appreciate. We work with organizations throughout the world to move our programs forward in an efficient and cost-effective manner. Atossa has two programs to develop therapies to treat COVID-19: One called the COVID-19 HOPE Program which uses AT-H201 for severely ill patients to improve lung function and reduce the amount of time that COVID-19 patients are on ventilators and another called AT-301 Nasal Spray for at-home use immediately following diagnosis of COVID-19 to proactively reduce symptoms of COVID-19 and to … Get stock quotes, news, fundamentals and easy to read SEC and SEDI insider filings. SEATTLE, June 11, 2020 -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of. We use cookies to ensure that we give you the best experience on our website. Latest ATOS Atossa Therapeutics Inc News Live. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. Home of the insider insights newsletter and the Canadian Insider Club which offers alerts and premium research.

Glock 23 Conversion Barrel 357, Humidity Sensor Switch Home Depot, Champions League 2020 Excel Template, D20 Roll Gif, Prep Urban Dictionary, Opposite Of To Say The Least, Low Fodmap Diet Pdf Uk, Lauren Or Laura, Secret Treasure Chest Dokkan, Bishop Robert Cosby Age, Jalen Mills Stats,